Medications to Induce Labor for Childbirth

(BLOOM Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen by Angela Bianco, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: Icahn School of Medicine at Mount Sinai

Disqualifiers: BMI < 30

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a randomized controlled trial examining whether the use of misoprostol or pitocin, in combination with a foley catheter, is more effective at inducing labor in patients with a gravid BMI that is considered obese.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug Misoprostol for inducing labor?

Research shows that Misoprostol (Cytotec) is effective for inducing labor, with more than 45 studies involving over 5400 women finding it more effective than oxytocin or prostaglandin E2 in achieving vaginal delivery within 24 hours. It also has lower cesarean delivery rates compared to oxytocin alone. ^{1 2 3 4 5}

Is it safe to use medications like Misoprostol and Oxytocin to induce labor?

Some studies have looked at the safety of using Misoprostol and Oxytocin to induce labor, but there are concerns about potential risks, including increased maternal and infant complications. It's important to discuss these risks with a healthcare provider. ^{5 6 7 8 9}

How does the drug misoprostol differ from other drugs for inducing labor?

Misoprostol (Cytotec) is unique because it is a prostaglandin E1 analogue that can be administered vaginally and is more effective than oxytocin or vaginal prostaglandin E2 in achieving vaginal delivery within 24 hours. However, it is not FDA-approved for use in pregnancy due to its abortifacient properties, and its use requires careful patient selection and monitoring. ^{2 3 10 11 12}

Research Team

Nicola F Tavella, MPH

Principal Investigator

Icahn School of Medicine at Mount Sinai

Angela Bianco, MD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

This trial is for pregnant individuals with a BMI of 30 or higher who are going to the hospital to start labor. It's not for those with a BMI under 30.

Inclusion Criteria

I am pregnant, have a BMI of 30 or more, and am going to be induced.

Exclusion Criteria

I am pregnant, going into labor, and my BMI is under 30.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants are randomized to receive either misoprostol or pitocin, in combination with a foley catheter, to induce labor

From start of induction until delivery

Follow-up

Participants are monitored for delivery outcomes, including whether delivery was vaginal or cesarean

At delivery

Treatment Details

Interventions

• Misoprostol (Prostaglandin Analog)
• Pitocin (Oxytocic)

Trial Overview The study is testing if using Misoprostol and Pitocin together, along with a foley catheter, is better at starting labor compared to just Pitocin and the catheter in patients considered obese.

Participant Groups

Group I: Pitocin only Active Control 1 Intervention

Patient receives pitocin and foley catheter for initial induction of labor, followed by more pitocin later on.

Group II: Misoprostol and Pitocin Active Control 2 Interventions

Patient receives misoprostol and foley catheter for initial induction of labor, followed by pitocin later on.

Misoprostol is already approved in Canada for the following indications:

Approved in Canada as Misoprostol for:

• Abortion
• Cervical Ripening
• Gynecological Conditions
• Duodenal Ulcer
• NSAID-Induced Ulcer Prophylaxis
• Stomach Ulcer
• Labor Induction
• Postpartum Bleeding

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials

933

Recruited

579,000+

Dr. Brendan Carr

Icahn School of Medicine at Mount Sinai

Chief Executive Officer since 2024

MD, MA, MS

Dr. Vicki LoPachin

Icahn School of Medicine at Mount Sinai

Chief Medical Officer

MD, FACP, MBA

Bronx Care Health System

Collaborator

Trials

1

Recruited

300+

Findings from Research

Vaginally administered misoprostol is as effective as dinoprostone for cervical ripening and labor induction, with similar mean time intervals to delivery and need for oxytocin augmentation in a study of 200 patients.

However, misoprostol was associated with a significantly lower incidence of tachysystole (7.1% vs. 18.4% for dinoprostone), indicating a potentially safer profile regarding uterine contractions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Wing, DA., Ortiz-Omphroy, G., Paul, RH.[2019]

In a study of 38 women with an unfavorable cervix, intravaginal misoprostol was found to significantly improve cervical readiness for labor compared to the standard treatment with PGE2 and oxytocin, with a median change in Bishop score of 4 versus 1 (P < 0.001).

Misoprostol also led to a higher rate of delivery within 36 hours (88% vs. 47%, P = 0.01), although it was associated with a higher incidence of tachysystole (8 cases vs. 0 in the control group, P < 0.01), indicating a need for monitoring for this side effect.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Misoprostol as a labor induction agent. Magtibay, PM., Ramin, KD., Harris, DY., et al.[2013]

The off-label use of Cytotec (misoprostol) for inducing labor has become more common, raising concerns about the safety and evidence behind such medical interventions during childbirth.

The article highlights two cases of unnecessary maternal and infant deaths linked to questionable medical practices, emphasizing the need for evidence-based approaches in childbirth to reduce morbidity and mortality.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The freedom to birth-the use of cytotec to induce labor: a non-evidence-based intervention. Oden, M., Certificate, D.[2021]

In a study of 77 pregnant women, titrated oral misoprostol was found to be highly effective for labor induction, with 93.5% achieving vaginal delivery within 24 hours and an average delivery time of 9.7 hours after induction.

The method demonstrated safety, as there were no cases of uterine hyperstimulation or induction failure, although 9.1% experienced uterine tachysystole, indicating that the dosage can be tailored to individual responses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pilot study of labor induction with titrated oral misoprostol. Cheng, SY., Chen, TC.[2013]

In a study of 276 patients, intravaginal Cytotec resulted in a shorter average time from induction to vaginal delivery (approximately 22 hours) compared to Oxytocin (approximately 25 hours).

Both Cytotec and Oxytocin showed similar rates of abdominal delivery, indicating that Cytotec is as effective as Oxytocin for labor induction without significant safety concerns.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Cytotec: an effective drug for the induction of labor]. Milchev, N., Kuzmanov, B., Terzhumanov, R.[2013]

In a study of 200 pregnant women, misoprostol was found to be highly effective for inducing labor in unfavorable conditions, with a failure rate of only 5% and a mean delivery time of 13.3 hours after administration.

The use of misoprostol was well tolerated, with a low incidence of uterine hyperstimulation (3.5%) and a cesarean section rate of 22%, indicating it is a safe option for labor induction.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Induction of labor by misoprostol, an analog of PGE1. A prospective study of 200 cases]. Chraibi, T., Aboulfalah, A., Bisbis, W., et al.[2013]

References

1. France pubmed.ncbi.nlm.nih.gov

[Rectal administration of misoprostol for delivery induced hemorrhage. Preliminary study]. [2013]

2. United States pubmed.ncbi.nlm.nih.gov

A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. [2019]

3. United States pubmed.ncbi.nlm.nih.gov

Induction of labor: the misoprostol controversy. [2019]

4. United States pubmed.ncbi.nlm.nih.gov

How to avoid iatrogenic morbidity and mortality while increasing availability of oxytocin and misoprostol for PPH prevention? [2016]

5. United States pubmed.ncbi.nlm.nih.gov

Misoprostol as a labor induction agent. [2013]

6. United States pubmed.ncbi.nlm.nih.gov

The freedom to birth-the use of cytotec to induce labor: a non-evidence-based intervention. [2021]

7. China (Republic : 1949- ) pubmed.ncbi.nlm.nih.gov

Pilot study of labor induction with titrated oral misoprostol. [2013]

8. Bulgaria pubmed.ncbi.nlm.nih.gov

[Cytotec: an effective drug for the induction of labor]. [2013]

9. United States pubmed.ncbi.nlm.nih.gov

A randomized comparison of oral misoprostol versus Foley catheter and oxytocin for induction of labor at term. [2019]

10. England pubmed.ncbi.nlm.nih.gov

Induction of labor. [2004]

11. England pubmed.ncbi.nlm.nih.gov

Vaginal misoprostol for cervical ripening and induction of labour. [2023]

12. France pubmed.ncbi.nlm.nih.gov

[Induction of labor by misoprostol, an analog of PGE1. A prospective study of 200 cases]. [2013]